{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T01:39:00Z","timestamp":1773970740510,"version":"3.50.1"},"reference-count":65,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2013,1,1]]},"DOI":"10.4140\/tcp.n.2013.39","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T21:45:35Z","timestamp":1357940735000},"page":"39-57","source":"Crossref","is-referenced-by-count":7,"title":["Use of Bisphosphonates in Older Adults: How Long Is Long Enough?"],"prefix":"10.4140","volume":"28","author":[{"given":"Rebecca L.","family":"Dunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2013,1,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing of stopping alendronate after 5 years of treatment. The fracture intervention trial long-term extension (FLEX): a randomized trial","volume":"296","author":"DM Black","year":"2006","journal-title":"JAMA"},{"key":"2","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"HG Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"3","unstructured":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva, Switzerland: World Health Organization; 1994 (WHO Technical Report Series, No. 843)."},{"key":"4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.16.S3.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis","volume":"16","author":"NB Watts","year":"2010","journal-title":"Endocr Pract"},{"key":"5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2165\/00003495-200666100-00004","article-title":"Treating osteoporosis with bisphosphonates and addressing adherence","volume":"66","author":"CH Chestnut","year":"2006","journal-title":"Drugs"},{"key":"6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11914-010-0007-2","article-title":"Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates","volume":"8","author":"JW Nieves","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11914-008-0018-4","article-title":"Management of osteoporosis in geriatric populations","volume":"6","author":"D Schneider","year":"2008","journal-title":"Curr Osteoporos Rep"},{"key":"8","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c4444","article-title":"Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort","volume":"341","author":"J Green","year":"2010","journal-title":"BMJ"},{"key":"9","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"JR Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.189","article-title":"Estimating bisphosphonates use and fracture reduction among US women aged 45 years and older, 2001-2008","volume":"26","author":"ES Siris","year":"2011","journal-title":"J Bone Miner Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"MT Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"CH III Chestnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1023\/A:1008626026484","article-title":"Bisphosphonates in bone diseases","volume":"20","author":"RW Sparidans","year":"1998","journal-title":"Pharm World Sci"},{"key":"14","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2165\/0003495-200868180-00011","article-title":"Ibandronate: a review of its use in the management of postmenopausal osteoporosis","volume":"68","author":"JE Frampton","year":"2008","journal-title":"Drugs"},{"key":"15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jama.2010.1098","article-title":"Exposure to oral bisphosphonates and risk of esophageal cancer","volume":"304","author":"CR Cardwell","year":"2010","journal-title":"JAMA"},{"key":"16","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2146\/ajhp080251","article-title":"Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates","volume":"66","author":"SN Gebara","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry","volume":"140","author":"P Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2146\/ajhp090506","article-title":"Risks and benefits of long-term bisphosphonate therapy","volume":"67","author":"GA Schmidt","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0b013e32833ad677","article-title":"Bisphosphonate adverse effects, lessons from large databases","volume":"22","author":"B Abrahamsen","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"DM Black","year":"1996","journal-title":"Lancet"},{"key":"21","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"SR Cummings","year":"1998","journal-title":"JAMA"},{"key":"22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"MR McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"23","doi-asserted-by":"crossref","first-page":"742","DOI":"10.7326\/0003-4819-136-10-200205210-00009","article-title":"Alendronate improved bone mineral density in elderly women with osteoporosis residing in long-term care facilities","volume":"136","author":"SL Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"key":"24","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","article-title":"Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old","volume":"52","author":"S Boonen","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"25","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"DM Black","year":"2007","journal-title":"N Engl J Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"KW Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","article-title":"Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older","volume":"58","author":"S Boonen","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/CIA.S8200","article-title":"Reducing hip fracture with risedronate in elderly women with established osteoporosis","volume":"4","author":"T Masud","year":"2009","journal-title":"Clinical Interventions in Aging"},{"key":"29","first-page":"26","article-title":"Effect of zoledronic acid 5mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: results from HORIZON-PFT","volume":"18","author":"J Cauley","year":"2007","journal-title":"Osteoporos Int"},{"key":"30","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/BOT.0b013e318172841c","article-title":"Low-energy femoral shaft fractures associated with alendronate use","volume":"22","author":"AS Neviaser","year":"2008","journal-title":"J Orthop Trauma"},{"key":"31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.injury.2007.08.036","article-title":"An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?","volume":"39","author":"EBK Kwek","year":"2008","journal-title":"Injury"},{"key":"32","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1056\/NEJMc0910389","article-title":"Atypical femoral fractures and bisphosphonate use","volume":"362","author":"CM Girgis","year":"2010","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"BA Lenart","year":"2009","journal-title":"Osteoporos Int"},{"key":"34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1302\/0301-620X.89B3.18146","article-title":"Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution","volume":"89","author":"SK Goh","year":"2007","journal-title":"J Bone Joint Surg Br"},{"key":"35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.injury.2008.09.010","article-title":"Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients","volume":"40","author":"W Ekstrom","year":"2009","journal-title":"Injury"},{"key":"36","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMe1003064","article-title":"Evolving data about subtrochanteric fractures and bisphosphonates","volume":"362","author":"E Shane","year":"2010","journal-title":"N Engl J Med"},{"key":"37","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"DM Black","year":"2010","journal-title":"N Engl J Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1359\/jbmr.081247","article-title":"Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study","volume":"24","author":"B Abrahamsen","year":"2009","journal-title":"J Bone Miner Res"},{"key":"39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"LY Park-Wyllie","year":"2011","journal-title":"JAMA"},{"key":"40","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"J Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"41","unstructured":"U.S. Food and Drug Administration. FDA drug safety communication: ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fractures. Available at http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203891.htm. Accessed November 1, 2010. <a target=\"_blank\" href='http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203891.htm'>http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm203891.htm<\/a>"},{"key":"42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc0808738","article-title":"Reports of esophageal cancer with oral bisphosphonate use","volume":"360","author":"DK Wysowski","year":"2009","journal-title":"N Engl J Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMc096026","article-title":"More on reports of esophageal cancer with oral bisphosphonate use","volume":"360","author":"B Abrahamsen","year":"2009","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s10620-010-1198-1","article-title":"Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus","volume":"55","author":"DM Nguyen","year":"2010","journal-title":"Dig Dis Sci"},{"key":"45","first-page":"1968","article-title":"Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age","volume":"32","author":"MP Ettinger","year":"2005","journal-title":"J Rheumatol"},{"key":"46","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1016\/j.joms.2009.07.097","article-title":"American Association of Oral Maxillofacial Surgeons position paper: bisphosphonate-related osteonecrosis of the jaws \u2014 2009 update: the need to refine the BRONJ","volume":"67","author":"G Colella","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"47","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systemic review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"SB Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"48","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMct1004903","article-title":"Bisphosphonates for osteoporosis","volume":"363","author":"MJ Favus","year":"2010","journal-title":"N Engl J Med"},{"key":"49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1210\/jc.2006-2013","article-title":"Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study","volume":"92","author":"NL Gilchrist","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"50","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/BOR.0b013e32832ca433","article-title":"Osteoporosis treatments and adverse events","volume":"21","author":"DH Solomon","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"51","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.joms.2008.11.015","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients","volume":"67","author":"TS Lazarovici","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"52","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1345\/aph.1Q239","article-title":"Osteonecrosis of the jaw in older osteoporosis patients treated with intravenous bisphosphonates","volume":"45","author":"J Baillargeon","year":"2011","journal-title":"Ann Pharmacother"},{"key":"53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jcms.2010.05.009","article-title":"Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence \u2013 a multi-centre study","volume":"39","author":"S Otto","year":"2011","journal-title":"J Cranio-Maxillo-Facial Surg"},{"key":"54","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.joms.2011.03.051","article-title":"Nationwide survey for bisphosphonate-related osteonecrosis of the jaws in Japan","volume":"69","author":"M Urade","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"55","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":"Use of alendronate and r isk of incident atrial fibrillation in women","volume":"168","author":"SR Heckbert","year":"2008","journal-title":"Arch Intern Med"},{"key":"56","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","article-title":"Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study","volume":"336","author":"HT Sorensen","year":"2008","journal-title":"BMJ"},{"key":"57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2796.2008.02065.x","article-title":"Atrial fibrillation in fracture patients treated with oral bisphosphonates","volume":"265","author":"B Abrahamsen","year":"2009","journal-title":"J Intern Med"},{"key":"58","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/jc.2010-2730","article-title":"Osteoporosis medication and reduced mortality risk in elderly women and men","volume":"96","author":"JR Center","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0003-9993(99)90133-8","article-title":"Intravenous pamidronate attenuated bone density loss after acute spinal cord injury","volume":"80","author":"PW Nance","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"key":"60","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1210\/jc.2007-2803","article-title":"Severely suppressed bone turnover and atypical skeletal fragility","volume":"93","author":"M Visekruna","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00198-009-1077-9","article-title":"Effect of once-yearly zoledronic acid on the spine and hip as measure by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial","volume":"21","author":"R Eastell","year":"2010","journal-title":"Osteoporos Int"},{"key":"62","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/bmj.39428.470752.AD","article-title":"Shifting the focus in fracture prevention from osteoporosis to falls","volume":"336","author":"TLN Jarvinen","year":"2008","journal-title":"BMJ"},{"key":"63","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures","volume":"18","author":"KL Stone","year":"2003","journal-title":"J Bone Miner Res"},{"key":"64","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1994.03510260060029","article-title":"Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly","volume":"271","author":"SL Greenspan","year":"1994","journal-title":"JAMA"},{"key":"65","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"JL Stock","year":"1997","journal-title":"Am J Med"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T01:34:00Z","timestamp":1498008840000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2013\/00000028\/00000001\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1,1]]}},"alternative-id":["2W1038035M382421"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2013.39","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1,1]]}}}